Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Accretion PharmaceuticalsNSE:ACCPL +5.00%18 Debt-to-EBITDA is 0.77 as of Mar. 2026, which is 73% below its 10-year median of 2.87. GuruFocus rates NSE:ACCPL with a GF Score™ of 18/100. The stock has 6 warning signs investors should review. Among 683 Drug Manufacturers companies, Accretion Pharmaceuticals ranks better than 65.89% on this metric.
Debt-to-EBITDA measures a company's ability to pay off its debt.
A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt. According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.
The historical rank and industry rank for Accretion Pharmaceuticals's Debt-to-EBITDA or its related term are showing as below:
NSE:ACCPL'
s Debt-to-EBITDA Range Over the Past 10 Years
Min: 0.81 Med: 2.87 Max: 4.06
Current: 0.81
During the past 5 years, the highest Debt-to-EBITDA Ratio of Accretion Pharmaceuticals was 4.06. The lowest was 0.81. And the median was 2.87.
NSE:ACCPL's Debt-to-EBITDA is ranked better than 65.89% of 683
companies
in the Drug Manufacturers industry
Industry Median: 1.63
vs NSE:ACCPL: 0.81
A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt.
According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.
Accretion Pharmaceuticals Debt-to-EBITDA Related Terms
Accretion Pharmaceuticals Debt-to-EBITDA Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
NSE:ACCPL vs LLY, JNJ, ABBV: Debt-to-EBITDA Comparison
For the Drug Manufacturers - General subindustry, Accretion Pharmaceuticals's Debt-to-EBITDA, along with its competitors' market caps and Debt-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Accretion Pharmaceuticals Debt-to-EBITDA vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Accretion Pharmaceuticals's Debt-to-EBITDA distribution charts can be found below:
* The bar in red indicates where Accretion Pharmaceuticals's Debt-to-EBITDA falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual Debt-to-EBITDA, the EBITDA of the last fiscal year is used. In calculating the annualized quarterly data,
the EBITDA data used here is two times the quarterly (Mar. 2026) EBITDA data.
Accretion Pharmaceuticals (NSE:ACCPL) has a Debt-to-EBITDA of 0.77 as of Mar. 2026. Debt-to-EBITDA ratio represents the ratio of total debt to total earnings before interest, taxes, depreciation and amortization. View historical data on Accretion Pharmaceuticals. This is 73% below median its historical median of 2.87. Over the past decade, Accretion Pharmaceuticals' Debt-to-EBITDA has ranged from 0.81 to 4.06. According to the industry distribution chart, Accretion Pharmaceuticals ranks #233 out of 683 companies in the Drug Manufacturers industry, placing it in the top 34.1%.
Is Accretion Pharmaceuticals' Debt-to-EBITDA too high?
Accretion Pharmaceuticals' current Debt-to-EBITDA of 0.77 is 73% below median its 10-year median of 2.87. Over the past 10 years, this metric has ranged from a low of 0.81 to a high of 4.06. The Drug Manufacturers industry median Debt-to-EBITDA is 1.63. Accretion Pharmaceuticals' value of 0.77 is 52.8% below this industry median. Based on the distribution chart, Accretion Pharmaceuticals ranks #233 out of 683 companies in the Drug Manufacturers industry, which is above the industry midpoint. Overall, Accretion Pharmaceuticals has a GF Score™ of 18/100, reflecting its overall financial health beyond just this single metric.
How does Accretion Pharmaceuticals' Debt-to-EBITDA compare to LLY and JNJ?
According to the Drug Manufacturers industry distribution chart, Accretion Pharmaceuticals ranks #233 out of 683 companies for Debt-to-EBITDA. This puts Accretion Pharmaceuticals in the upper half of its industry. The industry median Debt-to-EBITDA is 1.63. Accretion Pharmaceuticals' value of 0.77 is 52.8% below this benchmark. Historically, Accretion Pharmaceuticals' own Debt-to-EBITDA has ranged from 0.81 to 4.06 over the past decade. While the company's 10-year median is 2.87 vs. the industry median of 1.63, Accretion Pharmaceuticals has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Debt-to-EBITDA for a Drug Manufacturers company?
The median Debt-to-EBITDA among Drug Manufacturers companies is 1.63, based on 683 companies in the industry. Companies in the top quartile (top 25%) have a Debt-to-EBITDA significantly above this median, while those in the bottom quartile fall well below. However, Debt-to-EBITDA should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Accretion Pharmaceuticals's current Debt-to-EBITDA of 0.77 is 52.8% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Debt-to-EBITDA mean?
A high Debt-to-EBITDA can signal that a stock is expensive relative to its fundamentals. Debt-to-EBITDA ratio represents the ratio of total debt to total earnings before interest, taxes, depreciation and amortization. View historical data on Accretion Pharmaceuticals. For the Drug Manufacturers industry, the median Debt-to-EBITDA is 1.63 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Accretion Pharmaceuticals's current Debt-to-EBITDA is 0.77, which is 73% below median its own 10-year median of 2.87. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Accretion Pharmaceuticals stock overvalued right now?
Accretion Pharmaceuticals (NSE:ACCPL) has a current Debt-to-EBITDA of 0.77. The current Debt-to-EBITDA is 0.77, which is 73% below median its 10-year median of 2.87 and 52.8% below the Drug Manufacturers industry median of 1.63. Accretion Pharmaceuticals' overall GF Score™ is 18/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Debt-to-EBITDA calculated?
Debt-to-EBITDA is calculated from a company's financial statements. For Accretion Pharmaceuticals (NSE:ACCPL), the current Debt-to-EBITDA is 0.77 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Accretion Pharmaceuticals Ltd is engaged in the manufacturing of Medicinal & Pharmaceutical Products. The company manufactures tablets, oral liquid, capsule, cream, ointment, mouthwash, dusting powder, gel, ear drops, lotion, shampoo, powder, syrup, among others.
18GF Score
Get the complete analysis for NSE:ACCPL
Debt-to-EBITDA is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
NSE:ACCPL has been successfully added to your 
